KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Depreciation and Depletion (2018 - 2025)

Historic Depreciation and Depletion for Aquestive Therapeutics (AQST) over the last 8 years, with Q3 2025 value amounting to $139000.0.

  • Aquestive Therapeutics' Depreciation and Depletion fell 1257.86% to $139000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $565000.0, marking a year-over-year decrease of 3615.82%. This contributed to the annual value of $640000.0 for FY2024, which is 4449.26% down from last year.
  • Latest data reveals that Aquestive Therapeutics reported Depreciation and Depletion of $139000.0 as of Q3 2025, which was down 1257.86% from $140000.0 recorded in Q2 2025.
  • Over the past 5 years, Aquestive Therapeutics' Depreciation and Depletion peaked at $743000.0 during Q1 2021, and registered a low of $139000.0 during Q1 2025.
  • In the last 5 years, Aquestive Therapeutics' Depreciation and Depletion had a median value of $286000.0 in 2023 and averaged $388736.8.
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first surged by 1424.42% in 2023, then tumbled by 6259.54% in 2024.
  • Quarter analysis of 5 years shows Aquestive Therapeutics' Depreciation and Depletion stood at $717000.0 in 2021, then plummeted by 52.02% to $344000.0 in 2022, then grew by 14.24% to $393000.0 in 2023, then tumbled by 62.6% to $147000.0 in 2024, then dropped by 5.44% to $139000.0 in 2025.
  • Its Depreciation and Depletion was $139000.0 in Q3 2025, compared to $140000.0 in Q2 2025 and $139000.0 in Q1 2025.